3. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1
blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress …

Predicting patient outcome in multiple myeloma remains challenging despite the availability
of standard prognostic biomarkers. We investigated outcome for patients relapsing early …

Background Standard-of-care treatment for patients with newly diagnosed multiple
myeloma is bortezomib-based induction followed by high-dose melphalan and autologous …

Methods This series includes all patients treated with belantamab mafodotin monotherapy at
a standard dose (2.5 mg/kg) or dose reduction at the United Kingdom National Amyloidosis …

Introduction Multiple myeloma is a plasma cell malignancy that accounts for 1%–2% of newly
diagnosed cancers. At diagnosis, approximately 20% of patients can be identified, using …

Daratumumab, bortezomib and dexamethasone (DVd) is approved for patients with
relapsed multiple myeloma following the CASTOR phase 3 clinical trial. This retrospective …

Background. Outcomes in newly diagnosed multiple myeloma (MM) are influenced by genetic
risk by FISH or molecular profiling determined prior to therapy (Shah. V et al, 2022, DOI: …

The proteasome inhibitors, carfilzomib and bortezomib, are widely used to treat myeloma but
head-to-head comparisons have produced conflicting results. We compared the activity of …

Proteasome inhibitors have been associated with thrombotic microangiopathy (TMA) — a
group of disorders characterised by occlusive microvascular thrombosis causing …

Background Autologous stem cell transplantation (ASCT) and novel therapies have improved
the prognosis for patients with multiple myeloma (MM). For those who undergo ASCT …